Dianthus Therapeutics will present an interim responder analysis from Part A of its Phase 3 CAPTIVATE trial evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), with a company webcast set for March 9. No efficacy or safety figures were released ahead of the call, but the timing and standalone disclosure suggest the analysis is material to the trial’s progression.

The core development is an interim look at responder status in the first portion of a Phase 3 program, a design often used to enrich for patients likely to benefit before moving into a randomized or withdrawal phase. In CIDP, where background therapies and heterogeneous disease courses can dilute signals, a strong responder rate at this stage can de-risk the subsequent portion of the study by tightening event rates and clarifying powering assumptions. Conversely, a muted signal can force redesign or prolong enrollment. Dianthus flagging this analysis to investors implies it expects to clarify next steps for CAPTIVATE’s second phase, timelines, or both.

Strategically, putting a spotlight on interim enrichment fits the current CIDP competitive dynamic. The maintenance market is shifting beyond chronic IVIG and corticosteroids as newer immunomodulatory agents target durable disability reduction with more predictable supply chains and potentially less frequent administration. Sponsors are under pressure to show not just nominal improvements on disability scales but also operationally viable regimens that can displace established standards. If CAPTIVATE’s Part A shows a high proportion of clinically meaningful responders with acceptable tolerability, Dianthus would have the leverage to keep its Phase 3 tight, accelerate regulatory interactions, and define positioning against recently approved and late-stage entrants. If the signal is narrower or heavily subgroup-dependent, the company may need to recalibrate inclusion criteria or sample size, trading speed for robustness.

For sites, an enriched Phase 3 in CIDP has immediate implications. Screening efficiency and the ratio of enrolled to randomized patients hinge on how “responder” is defined and verified, which can drive staffing for assessments and visit cadence. If the trial uses a run-in to identify responders, sites can expect a premium on adherence, early symptom stabilization, and consistent application of functional scales, with associated monitoring and data-cleaning demands. CROs and technology vendors will need to support rapid adjudication of responder status, flexible randomization workflows, and tighter data visibility to prevent drifts in scale administration across regions. Payers and regulators will scrutinize the generalizability of any enriched signal; demonstrating consistency across geographies and baseline severity strata will matter as FDA and other agencies continue to push for broader representativeness and clarity on durability endpoints in CIDP.

The larger market context also raises executional questions that CAPTIVATE’s interim readout may not fully answer. Route of administration, dosing interval, and the feasibility of community or home-based care will be pivotal against entrenched infusion paradigms and emerging subcutaneous options. Supply chain reliability and patient services infrastructure are increasingly gating factors for adoption in neuromuscular disorders, where continuity of therapy is tightly linked to functional outcomes. On the evidence front, durability beyond the initial response window and reductions in relapse rates will likely determine regulator and payer enthusiasm more than early responder counts alone.

The next milestone is clear: how Dianthus translates the interim responder analysis into a confirmed Part B design, updated timelines, and regulatory dialogue. Watch for specifics on responder definitions, enrichment magnitude, and any protocol amendments that indicate confidence in effect size. Equally important will be signals on safety monitoring intensity and discontinuation rates, which can materially affect real-world uptake even in the presence of efficacy. If the company can pair a clean enrichment signal with a pragmatic operational profile, CAPTIVATE could move quickly; if not, expect a longer path with a premium on trial optimization and geographic diversification to preserve momentum.

Source link: https://www.globenewswire.com/news-release/2026/03/08/3251470/0/en/Dianthus-Therapeutics-to-Host-Conference-Call-and-Webcast-to-Discuss-the-Interim-Responder-Analysis-Results-of-the-Phase-3-Captivate-Trial-of-Claseprubart-in-Chronic-Inflammatory-D.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.